CONMED (CNMD)
(Delayed Data from NYSE)
$73.22 USD
-0.74 (-1.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $73.21 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$73.22 USD
-0.74 (-1.00%)
Updated Aug 30, 2024 04:00 PM ET
After-Market: $73.21 -0.01 (-0.01%) 7:58 PM ET
4-Sell of 5 4
B Value B Growth F Momentum B VGM
Zacks News
Hill-Rom (HRC) Rides on International Growth, New Launches
by Urmimala Biswas
Hill-Rom (HRC) launches RetinaVue 700 Imager, EarlySense and WatchCare in 2019.
LHC Group Expands Partnership With Ochsner Health System
by Zacks Equity Research
LHC Group (LHCG) sees major expansion in partnerships of late.
Here's Why You Should Add DexCom (DXCM) to Your Portfolio
by Zacks Equity Research
DexCom (DXCM) raises its 2019 revenue and EPS guidance.
Here's Why You Should Hold on to Allscripts Stock for Now
by Zacks Equity Research
Allscripts (MDRX) is gaining steadily from strategic acquisitions and solid prospects in Sunrise EHR platform. However, integration risks remain a woe.
Here's Why You Should Bet on Integer Holdings Stock Now
by Zacks Equity Research
Integer Holdings (ITGR) continues to benefit from portfolio management, strong foothold in the broader MedTech space and rising Non-Medical sales.
LHC Group Expands Partnership With Tennessee-Based Medalogix
by Zacks Equity Research
Management at LHC Group (LHCG) expects to complete the expansion by the first quarter of 2020.
Here's Why You Should Invest in Cardinal Health Stock Now
by Zacks Equity Research
Cardinal Health (CAH) is gaining from diversified product portfolio and robust pharmaceutical segment.
McKesson, Walgreens Form JV for European Pharmaceutical Unit
by Zacks Equity Research
The VA selects McKesson (MCK) as their prime pharmaceutical supplier.
NextGen Healthcare Boosts Patient Care With CHC Strategies
by Zacks Equity Research
NextGen Healthcare (NXGN) is likely to boost presence in health management with CHC Strategies delivering quality medical care through the company's Population Health platform.
LHC Group Set to Gain From Expansion of LifePoint Health JV
by Zacks Equity Research
LHC Group (LHCG) expects approximately $5.4 million in annualized revenues from this transaction.
Are You Looking for a Top Momentum Pick? Why Conmed (CNMD) is a Great Choice
by Zacks Equity Research
Does Conmed (CNMD) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here's Why You Should Retain NextGen Healthcare for Now
by Zacks Equity Research
NextGen Healthcare (NXGN) is gaining traction from the U.S. RCM market and the growing EHR market. However, margin pressure remains a concern.
Here's Why You Should Retain Wright Medical Stock For Now
by Zacks Equity Research
Wright Medical (WMGI) is gaining traction from strong international presence and robust product portfolio. However, adverse forex continues to raise concerns.
Here's Why You Should Hold on to Ecolab (ECL) Stock for Now
by Zacks Equity Research
Ecolab (ECL) slashes 2019 EPS view owing to foreign exchange headwinds.
Here's Why You Should Hold on to Cerner (CERN) Stock Now
by Zacks Equity Research
Cerner (CERN) is gaining traction from prudent strategic deals and big data based EHR system. However, weak margins remain a woe.
Here's Why You Should Retain Nevro (NVRO) Stock for Now
by Zacks Equity Research
Nevro (NVRO) is gaining traction from strengthening international footprint and solid prospects in the SCS market. However, stiff competition remains a woe.
Here's Why You Should Hold on to HealthEquity (HQY) for Now
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
HealthEquity (HQY) Earnings & Revenues Beat Estimates in Q3
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, HealthEquity (HQY) raises its fiscal 2020 view.
Here's Why You Should Hold On to HMS Holdings (HMSY) Stock
by Zacks Equity Research
HMS Holdings (HMSY) is gaining traction from growing PI and TPM analytical services. However, high debt continues to raise concerns.
Here's Why You Should Add Veeva (VEEV) to Your Portfolio Now
by Zacks Equity Research
Buoyed by a solid fiscal third quarter, Veeva (VEEV) raises its fiscal 2020 revenue guidance.
Intuitive Surgical (ISRG) Boosts da Vinci System With FDA Nod
by Zacks Equity Research
Intuitive Surgical (ISRG) is likely to strengthen its da Vinci surgical system with the recent FDA nod.
Veeva Systems (VEEV) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Veeva (VEEV) gains from solid segmental contributions in fiscal third quarter, raises fiscal 2020 view.
Here's Why You Should Retain McKesson (MCK) Stock for Now
by Zacks Equity Research
McKesson (MCK) is gaining from strong segmental performance and solid prospects in the pharmaceutical and medical supplies distribution market. However, rising pricing pressure remains a concern.
Here's Why You Should Hold on to Varian (VAR) Stock for Now
by Zacks Equity Research
Varian (VAR) gains from Oncology unit, deals with weakness in the Proton Therapy segment.
Here's Why You Should Hold on to Pacific Biosciences Stock
by Zacks Equity Research
Pacific Biosciences (PACB) continues to gain from innovative product portfolio and Sequel system. However, stiff competition remains a woe.